Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells

A number of agents designed for immunotherapy of Acute Myeloid Leukemia (AML) are in preclinical and early clinical development. Most of them target a single antigen on the surface of AML cells. Here we describe the development and key biological properties of a tri-specific agent, the dual-targetin...

Descripción completa

Detalles Bibliográficos
Autores principales: Braciak, Todd A., Roskopf, Claudia C., Wildenhain, Sarah, Fenn, Nadja C., Schiller, Christian B., Schubert, Ingo A., Jacob, Uwe, Honegger, Annemarie, Krupka, Christina, Subklewe, Marion, Spiekermann, Karsten, Hopfner, Karl-Peter, Fey, Georg H., Aigner, Michael, Krause, Stefan, Mackensen, Andreas, Oduncu, Fuat S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140553/
https://www.ncbi.nlm.nih.gov/pubmed/30228941
http://dx.doi.org/10.1080/2162402X.2018.1472195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140553/
https://www.ncbi.nlm.nih.gov/pubmed/30228941
http://dx.doi.org/10.1080/2162402X.2018.1472195

Ejemplares similares